Literature DB >> 16005223

1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.

John W Huffman1, Paul V Szklennik, Amanda Almond, Kristen Bushell, Dana E Selley, Hengjun He, Michael P Cassidy, Jenny L Wiley, Billy R Martin.   

Abstract

A new class of cannabimimetic indoles, with 3-phenylacetyl or substituted 3-phenylacetyl substituents, has been prepared and their affinities for the cannabinoid CB1 and CB2 receptors have been determined. In general those compounds with a 2-substituted phenylacetyl group have good affinity for both receptors. The 4-substituted analogs have little affinity for either receptor, while the 3-substituted compounds are intermediate in their affinities. Two of these compounds, 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251) and 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302), have 5-fold selectivity for the CB1 receptor with modest affinity for the CB2 receptor. GTPgammaS determinations indicate that both compounds are highly efficacious agonists at the CB1 receptor and partial agonists at the CB2 receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005223     DOI: 10.1016/j.bmcl.2005.06.008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

1.  Detection and disposition of JWH-018 and JWH-073 in mice after exposure to "Magic Gold" smoke.

Authors:  Justin L Poklis; Dorra Amira; Laura E Wise; Jason M Wiebelhaus; Brenda J Haggerty; Alphonse Poklis
Journal:  Forensic Sci Int       Date:  2012-03-08       Impact factor: 2.395

2.  Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to 'buzz' smoke by HPLC/MS/MS.

Authors:  Justin L Poklis; Dorra Amira; Laura E Wise; Jason M Wiebelhaus; Brenda J Haggerty; Aron H Lichtman; Alphonse Poklis
Journal:  Biomed Chromatogr       Date:  2012-03-08       Impact factor: 1.902

Review 3.  Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.

Authors:  A Poso; J W Huffman
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

4.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

Review 5.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

Review 6.  Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Top Behav Neurosci       Date:  2017

7.  Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine.

Authors:  Allan J Barnes; Sheena Young; Eliani Spinelli; Thomas M Martin; Kevin L Klette; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2014-04-24       Impact factor: 2.395

8.  CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.

Authors:  Ramy Khella; Jennifer L Short; Daniel T Malone
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

9.  Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Authors:  Kimberly L Samano; Justin L Poklis; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-05-09       Impact factor: 3.367

10.  Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.

Authors:  S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.